XML 60 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Other Intangible Assets, Net
3 Months Ended
Mar. 31, 2012
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Other Intangible Assets Disclosure

6.       Other intangible assets, net

  March 31,December 31,
  20122011
  $’M $’M
  ________________________________
Amortized intangible assets  
 Intellectual property rights acquired for currently marketed products2,520.42,500.7
 Acquired product technology710.0710.0
 Other intangible assets45.923.2
  ________________________________
  3,276.33,233.9
Unamortized intangible assets  
 Intellectual property rights acquired for In-process R&D (“IPR&D”)123.2119.8
  ________________________________
  3,399.53,353.7
    
Less: Accumulated amortization(910.5)(860.7)
  ________________________________
  2,489.02,493.0
  ________________________________

As at March 31, 2012 the net book value of intangible assets allocated to the SP segment was $ 1,357.8 million (December 31, 2011: $1,348.3 million), to the HGT segment was $449.6 million (December 31, 2011: $453.2 million) and to the RM segment was $681.6 million (December 31, 2011: $691.5 million).

 

The change in the net book value of other intangible assets for the three months to March 31, 2012 and 2011 is shown in the table below:

 Other intangible assets
 20122011
 $’M$’M
 ________________________________
As at January 1, 2,493.01,978.9
Acquisitions22.0-
Amortization charged (45.8)(36.1)
Foreign currency translation19.843.0
 ________________________________
As at March 31, 2,489.01,985.8
 ________________________________

Management estimates that the annual amortization charge in respect of intangible assets held at March 31, 2012 will be approximately $191 million for each of the five years to March 31, 2017. Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products.